19.10.2015
- AstraZeneca’s US launch of a fixed-dose diabetes drug combination of saxagliptin and dapagliflozin has been delayed, due to concerns of the Food and Drug Administration (FDA). In a...
11.07.2013
- Roche will halt development of a diabetes drug partly because of its undesired side-effects, marking another high-profile setback for the Swiss company as it struggles to diversify...
07.06.2013
- U.S. health advisers voted on Thursday to recommend relaxing market restrictions on GlaxoSmithKline's diabetes drug Avandia, the former blockbuster at the center of one of the...
29.04.2013
- Pfizer and Merck & Co said they will co-develop Pfizer's experimental type 2 diabetes drug ertugliflozin, both as a standalone product and in combination with other drugs...
27.04.2012
- Danish drugmaker Novo Nordisk said it expected its U.S. insulin market share to improve and edged up its full-year targets after stiff competition for insulin and disappointing...
